A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Vergote, I; Dean, E; Lassen, U; de Bono, J; Drew, Y; Machiels, J-P; Nielsen, D; ... Hong, DS; + view all Vergote, I; Dean, E; Lassen, U; de Bono, J; Drew, Y; Machiels, J-P; Nielsen, D; Arkenau, H-T; Forster, M; Jones, R; Slomovitz, B; Spicer, J; Johnson, M; Cornez, N; Gennigens, C; Fulton, B; Lisby, S; Basse, L; Coleman, R; Hong, DS; - view fewer (2017) A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Presented at: 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain.

http://ift.tt/2BgVGH9